In this review we summarize recent work on the molecular basis of apop
tosis in the murine B cell lymphoma WEHI-231. WEHI-231 cells undergo a
poptosis in response to antigen receptor cross-linking with anti-Ig re
agents. Death is specifically triggered via surface IgM (sIgM); cross-
linking sIgD, Ia or FcR has no effect. Apoptosis is preceded by growth
arrest in the G(0)/G(1) phase of the cell cycle and may not occur in
all currently available WEHI-231 sublines. The continuous passage of W
EHI-231 cells in different laboratories has yielded variants that diff
er greatly in their response to anti-Ig treatment because apoptotic ce
lls tend to be negatively selected in culture. Resistant and susceptib
le variants undergo growth arrest in response to anti-Ig but only susc
eptible cells go on to die by apoptosis. Cells resistant to anti-Ig ha
ve intact apoptotic machinery as indicated by their susceptibility to
dexamethasone, irradiation and other treatments. However, anti-Ig-resi
stant cells are also resistant to apoptosis induced by the immunosuppr
essants cyclosporin A, FK-506 and rapamycin. We discuss the experiment
al evidence indicating that the apoptotic machinery in WEHI-231 cells
is pre-activated but under constant negative regulation by short-lived
protein inhibitors. Inhibition is removed by a mediator released in r
esponse to anti-Ig treatment in susceptible sublines. The mediator of
death is the sphingosine derivative, ceramide, presumably produced by
membrane sphingomyelinases activated by anti-Ig. A hypothetical model
on how ceramide kills WEHI-231 is presented.